Young children (2 – 12 yrs) frequently experience pain from teething, minor injuries, mild fever, post-vaccination soreness, headaches, rhinitis-related ENT discomfort, persistent cough and other common ailments. Caregivers typically rely on over the counter (OTC) analgesics (acetaminophen, ibuprofen) whose adult-derived formats pose challenges: bitter taste, swallowing difficulty, dosing errors, and parental anxiety over repeat administration or long-term safety.
Growing consumer interest in non-drug or low-dose approaches (wearables, neuro-stimulation, botanical actives, psychological techniques) adds complexity: products must be evidence-based and easy to adopt, yet still affordable and widely accessible. A new generation of child-centric pain-relief solutions—combining formulation science, digital health and human-factors design—can close this gap.
We are looking for innovative, scalable technologies (pharmaceutical, non-pharmacological or hybrid) that deliver safe, effective, and caregiver-friendly pain relief tailored specifically to children. Solutions should be available over the counter (OTC) and improve one or more of: dosing precision, onset time, palatability/acceptance, convenience, safety profile, or caregiver guidance.
Our global team is dedicated to developing and collaborating on future-facing, scientifically proven, consumer-focused innovations and technologies. We believe that true innovation comes from collaboration and partnerships with start-ups, academia, health tech pioneers, and innovators.
Haleon has a strong portfolio of consumer health brands and plays a vital role for people all around the world, in a sector that is growing and more relevant than ever. We have five brand categories: Oral Health, Vitamins, Minerals and Supplements(VMS), Pain, Respiratory & Digestive. Our trusted brands like Sensodyne, Advil, Centrum & Voltaren improve the lives of millions globally.
Learn more

The Q&A is now closed.